— Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin — — Independent appraisal committee votes that oral semaglutide provides a superior net health benefit over background therapy alone, achieves intermediate long-term value for money, and may be an attractive alternative for patients who would prefer an […]
Read More
12/09/2019
Boston, Mass. And San Francisco, Calif., March 14, 2016 – The Institute for Clinical and Economic Review (ICER) has released two final reports titled Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks and Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks. […]
Read More
03/14/2016
– New Report from New England CEPAC Identifies NPH insulin as a High Value Treatment Option Relative to Costlier, Analog Formulations– Boston, Mass., December 22, 2014 – The New England Comparative Effectiveness Public Advisory Council (CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), has released a final evidence report, titled […]
Read More
12/22/2014
Public Comments
Closed